The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
A novel presenilin 1 mutation associated with Pick's disease but not β‐amyloid plaques
Abstract
Familial forms of frontotemporal dementia (FTD) with tauopathy are mostly caused by mutations in the gene encoding the microtubule‐associated protein tau (MAPT). However, rare forms of familial tauopathy without MAPT mutations have been reported, suggesting other tauopathy‐related genetic defects. Interestingly, two presenilin 1 (PS1) mutations (Leu113Pro and insArg352) recently have been associated with familial FTD albeit without neuropathological confirmation. We report here a novel PS1 mutation in a patient with Pick‐type tauopathy in the absence of extracellular β‐amyloid deposits. The mutation is predicted to substitute Gly→Val at codon position 183 (Gly183Val) and to affect the splice signal at the junction of the sixth exon and intron. Further clinical‐genetic investigation showed a positive family history of FTD‐like dementia and suggested that Gly183Val is associated with a phenotypically heterogeneous neurodegenerative disorder. Our results suggest PS1 as a candidate gene for Pick‐type tauopathy without MAPT mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 2×
“However, functional in vivo studies directly supporting this idea are lacking, and no striking phenotypes have been observed in mice lacking one copy of PS1.”
BackgroundClinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965
Dense-Core Senile Plaques in the Flemish Variant of Alzheimer's Disease Are Vasocentric
Kumar-Singh, S., Cras, P., Wang, R., Kros, J. M., van Swieten, J., Lübke, U., Ceuterick, C., Serneels, S., Vennekens, K., Timmermans, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64207-1 · Cited by 114
Self-citationDermaut, B. (2001) · Brain · doi:10.1093/brain/124.12.2383 · Cited by 74 · cited 2×
“Constructs of the previously reported neuropathologically confirmed early-onset AD mutations Ile143Thr and Leu282Val were used as positive controls.(9,25) Human embryonic kidney Flp-In (Flp-In-293; Invitrogen) cells stably expressing APPKM670/671NL were cultured and transfected as described.”
BackgroundMethodSelf-citationLambert, J.-C., Mann, D. M. A., Harris, J. M., Chartier-Harlin, M.-C., Cumming, A., Coates, J., Lemmon, H., StClair, D., Iwatsubo, T., & Lendon, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.6.353 · Cited by 61
Cited by
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Self-citationŠimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., De Silva, R., Di Giovanni, G., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 703
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
“Several examples of white atter abnormalities in symptomatic PS1 mutation carriers ave been published (Dermaut et al., 2004; Marrosu et al., 006; O’Riordan et al., 2002).”
Neary, D., Snowden, J., & Mann, D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70223-4 · Cited by 526
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485
GSK-3 is essential in the pathogenesis of Alzheimer's disease
Takashima, A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s335 · Cited by 396
The role of cerebral amyloid β accumulation in common forms of Alzheimer disease
Gandy, S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25100 · Cited by 385
Sun, L., Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618657114 · Cited by 382
De Strooper, B. (2007) · EMBO reports · doi:10.1038/sj.embor.7400897 · Cited by 351
Loy, C. T., Schofield, P. R., Turner, A. M., & Kwok, J. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60630-3 · Cited by 342
Genetic insights in Alzheimer's disease
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70259-4 · Cited by 290
Self-citationTau phosphorylation and aggregation in Alzheimer's disease pathology
Avila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.067 · Cited by 282
Larner, A. J., & Doran, M. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0019-5 · Cited by 256
Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations
Van Swieten, J., & Spillantini, M. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00052.x · Cited by 195
Kitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178
“This observation is in part supported by clinical evidence from individuals who possess this unique PS1 mutation and develop frontotemporal dementia (FTD)/Pick's disease with aberrant tau deposits but no A pathology [79-84].”
BackgroundSaura, C. A., Chen, G., Malkani, S., Choi, S.-Y., Takahashi, R. H., Zhang, D., Gouras, G. K., Kirkwood, A., Morris, R. G. M., & Shen, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1247-05.2005 · Cited by 157
Landman, N., Jeong, S. Y., Shin, S. Y., Voronov, S. V., Serban, G., Kang, M. S., Park, M. K., Di Paolo, G., Chung, S., & Kim, T.-W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604954103 · Cited by 149
van der Zee, J., Rademakers, R., Engelborghs, S., Gijselinck, I., Bogaerts, V., Vandenberghe, R., Santens, P., Caekebeke, J., De Pooter, T., Peeters, K., et al. (2006) · Brain · doi:10.1093/brain/awl029 · Cited by 90
“One is the familial patient, which we reported previously (Dermaut et al., 2004), who carried a PSEN1 Gly183Val mutation and had pathologically confirmed Pick’s disease.”
BackgroundSelf-citationDeposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease
Sepulveda‐Falla, D., Matschke, J., Bernreuther, C., Hagel, C., Puig, B., Villegas, A., Garcia, G., Zea, J., Gomez‐Mancilla, B., Ferrer, I., et al. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00469.x · Cited by 82
Presenilins in synaptic function and disease.
Ho, A., & Shen, J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.002 · Cited by 52
“Both the Leu113Pro and the Gly183Val PS1 mutations reside in exon/intron boundaries, suggesting that these mutations can affect proper splicing, and the Gly183Val mutation has been confirmed neuropathologically to have Pick’s tauopathy in the absence of amyloid deposition [3].”
Microtubule transport defects in neurological and ciliary disease
Gerdes, J. M., & Katsanis, N. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5007-5 · Cited by 51
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Nizzari, M., Barbieri, F., Gentile, M. T., Passarella, D., Caorsi, C., Diaspro, A., Taglialatela, M., Pagano, A., Colucci-D'Amato, L., Florio, T., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101590 · Cited by 21
Metadata
- Authors
- Dermaut, B., Kumar‐Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., Pickut, B. A., Peeters, K., Van Den Broeck, M., Vennekens, K., Claes, S., Cruts, M., Cras, P., Martin, J., Van Broeckhoven, C., & De Deyn, P. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-04-26
- Volume
- 55
- Issue
- 5
- Pages
- 617-626
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2010625082
- Cited by
- 212
- References
- 9
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.